Michael P. Samar - 25 May 2022 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Reporting relationship: Director
Issuer ticker: UBX
Reported as of: 25 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2022, 17:19:25 UTC
Prior SEC filing: 31 Mar 2022
Next SEC filing: 27 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Alexander Hieu Nguyen, Attorney-in-Fact for Michael P. Samar

Key filing fact

Michael P. Samar filed Form 4 for Unity Biotechnology, Inc. (UBX) on 26 May 2022.

Key facts

This page summarizes Michael P. Samar's Form 4 filing for Unity Biotechnology, Inc. (UBX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 May 2022, 17:19.

Change

Previous filing in this sequence was filed on 31 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UBX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 25 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.7600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 36-month period commencing on May 25, 2022 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.